For journalists & analysts.
This page is the entry point for media coverage. Below: company facts, brand assets, an embargo policy, and a direct line to our press contact.
Press contact
For all media inquiries — interviews, expert commentary on epilepsy AI, product reviews, analyst briefings — write to clinical@nsai.fi. We respond to credentialed press within two business days.
Include: outlet, deadline, angle, and whether the request is on or off the record.
Fact sheet
| Legal name | Neuro Scan AI Solutions Oy |
|---|---|
| Y-tunnus (business ID) | 3437722-8 |
| Headquarters | Espoo, Finland |
| Project offices | New York · Amsterdam · Helsinki |
| Founder & CEO | Dr. Serkan Yıldırım, PhD (Computer Sciences) |
| Sector | Clinical AI · Medical device software · Neurology |
| Primary product | Real-time epileptic seizure detection from scalp EEG (22-channel, cross-subject validated on public dataset) |
| Validation dataset | CHB-MIT scalp EEG database (PhysioNet) — leave-one-patient-out cross-subject |
| Current stage | Pre-pilot. Mobile app and reference hardware are built. Algorithm is dataset-validated. No live patient EEG processed in a hospital setting yet. |
| Ethics review | Applications submitted at four sites: two hospitals in Turkey, one in Helsinki (Finland), one in the United States. Partner names will be released as each partner consents. |
| Regulatory roadmap | EU MDR (Regulation 2017/745) — Class IIa software-as-medical-device pathway. ISO 13485 QMS and technical documentation in build. CE-MDR submission depends on clinical pilot data. |
Brand assets
Logos, founder headshots, product screenshots, and a one-page fact sheet (PDF) are available on request from clinical@nsai.fi.
When you write about us:
- Full name on first mention: Neuro Scan AI Solutions.
- Short form thereafter: Neuro Scan, or NSAS.
- Do not use "NeuroScan" (one word), "NSA," or other variants.
- Logo lockup: coral / rust mark on dark backgrounds; blue alt on light. Do not recolor.
Embargo & exclusives
We honor embargoes when agreed in writing in advance. Embargo violations end the working relationship — please do not test this.
For exclusives on funding rounds, regulatory milestones, or clinical results, contact clinical@nsai.fi at least three weeks ahead of the planned story. We work with one outlet per market per news cycle.
What we will and will not comment on
- Yes: our methodology, the published research underpinning the model, our pre-pilot status, the regulatory landscape for AI in neurology, our hiring plans, named clinical partners (once partners consent).
- No: revenue, valuation, investor names, unannounced product features, ongoing regulatory correspondence, the names of the four hospitals under ethics review until those partners consent to disclosure, patient-identifiable case studies.
- Specifically not: we have not yet processed real patient EEG in a hospital. Any reporting that frames us as currently live in hospitals is inaccurate. Please contact us before publishing if uncertain.